Gastroenterology
Fatty Liver
1
Pipeline Programs↗
2
Active Trials↗
1
Companies Involved↗
Fatty Liver is an early-stage landscape with 1 program across 1 company. The most active players are Getz Pharma. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved1
Analysis
Trial Status
11
clinical trials
Completed5 · 45%
Unknown status2 · 18%
Terminated2 · 18%
Not yet recruiting2 · 18%
Clinical Trials
Trial Activity
11 trials
Efficacy and Safety of Fuzheng Huayu Tablets in Patients With Metabolic Dysfunction-Associated Fatty Liver Cirrhosis (Compensated): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study
Not yet recruiting·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Approved·NCT07663643·459 enrolled
Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00323414·37 enrolled
Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT01792115·22 enrolled
Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism
Terminated·—·Phase 4·NCT02721888·127 enrolled
Anti-diabetic Drugs and Fatty Liver Management
Unknown status·—·N/A·NCT05041673·120 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)